To the Editor: Although the observations of Dr Kesselheim and colleagues1 are generally accurate, the authors oversimplified the issue and did not adequately consider all of the evidence. They largely grouped the material they reviewed into clinical trials and editorials. The former were appropriately given more weight in the authors' conclusions. However, case report material in some editorials as well as in articles that were not included2 (such as reports of serious arrhythmic recurrences, proarrhythmic events, and deaths in association with formulation substitution of an antiarrhythmic drug) was ignored.
Reiffel JA. Equivalence of Generic and Brand-Name Drugs for Cardiovascular Disease. JAMA. 2009;301(16):1654-1656. doi:10.1001/jama.2009.522